Skip to main content Skip to section navigation Skip to footer
180 Life Sciences Corp.
  • Home
  • Home
  • About Us
  • Programs
    • Anti-TNF
    • Synthetic CBD Analogs (SCAs)
    • a7nAChR Program
  • Pipeline
  • Leadership
  • Investors
  • Contact Us
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
    Jul 01, 2025 7:30am EDT

    180 Life Sciences Corp. Announces Strengthening of Legacy Intellectual Property Assets

    May 01, 2025 9:30am EDT

    180 Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Covering Novel Method to Prevent or Reduce Post-Operative Cognitive Dysfunction

    Apr 30, 2025 8:30am EDT

    180 Life Sciences Corp. Announces Share Repurchase

    rss_feed News RSS
    • Email Alerts
    • Contacts
    • RSS News Feed
    © Copyright 2012 - 2025 | 180 Life Sciences Corp. | All Rights Reserved.
    • Visit us on Twitter Twitter
    • Visit us on Linkedin Linkedin